Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging.

Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR.

Radiology. 2010 Jul;256(1):176-83. doi: 10.1148/radiol.10091147. Epub 2010 May 26.

2.

Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance.

Flavell RR, Westphalen AC, Liang C, Sotto CC, Noworolski SM, Vigneron DB, Wang ZJ, Kurhanewicz J.

Abdom Imaging. 2014 Oct;39(5):1027-35. doi: 10.1007/s00261-014-0136-7.

3.
4.

Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume.

Westphalen AC, Koff WJ, Coakley FV, Muglia VF, Neuhaus JM, Marcus RT, Kurhanewicz J, Smith-Bindman R.

Radiology. 2011 Nov;261(2):477-86. doi: 10.1148/radiol.11110457. Epub 2011 Aug 24.

5.

Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?

Abd-Alazeez M, Ahmed HU, Arya M, Allen C, Dikaios N, Freeman A, Emberton M, Kirkham A.

Urol Oncol. 2014 Aug;32(6):741-7. doi: 10.1016/j.urolonc.2014.01.008. Epub 2014 Jun 26.

PMID:
24981993
6.

Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?

Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR, Agarwal H, Shah V, Bernardo M, Pang Y, Daar D, McKinney YL, Linehan WM, Kaushal A, Merino MJ, Wood BJ, Pinto PA, Choyke PL.

Radiology. 2013 Jul;268(1):144-52. doi: 10.1148/radiol.13121325. Epub 2013 Mar 6.

7.

Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.

Casciani E, Polettini E, Bertini L, Emiliozzi P, Amini M, Pansadoro V, Gualdi GF.

Radiol Med. 2004 Nov-Dec;108(5-6):530-41. English, Italian.

PMID:
15722999
8.

Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study.

Puech P, Rouvière O, Renard-Penna R, Villers A, Devos P, Colombel M, Bitker MO, Leroy X, Mège-Lechevallier F, Comperat E, Ouzzane A, Lemaitre L.

Radiology. 2013 Aug;268(2):461-9. doi: 10.1148/radiol.13121501. Epub 2013 Apr 11.

PMID:
23579051
9.

Prostate cancer: is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance?

Cabrera AR, Coakley FV, Westphalen AC, Lu Y, Zhao S, Shinohara K, Carroll PR, Kurhanewicz J.

Radiology. 2008 May;247(2):444-50. doi: 10.1148/radiol.2472070770.

10.

Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.

Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA.

Radiology. 2005 Mar;234(3):804-14.

PMID:
15734935
11.

Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.

Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):370-7. doi: 10.1016/j.ijrobp.2012.04.028. Epub 2012 Jun 4.

PMID:
22672747
12.

MR imaging-guided focal laser ablation for prostate cancer: phase I trial.

Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, Watson S, Eggener S.

Radiology. 2013 Jun;267(3):932-40. doi: 10.1148/radiol.13121652. Epub 2013 Feb 25.

PMID:
23440319
13.

Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging.

Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, Nelson SJ, Vigneron DB.

Radiology. 1998 Mar;206(3):785-90.

PMID:
9494502
14.

Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.

Vargas HA, Akin O, Shukla-Dave A, Zhang J, Zakian KL, Zheng J, Kanao K, Goldman DA, Moskowitz CS, Reuter VE, Eastham JA, Scardino PT, Hricak H.

Radiology. 2012 Nov;265(2):478-87. doi: 10.1148/radiol.12120041. Epub 2012 Sep 5.

15.

Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.

Keefe DT, Schieda N, El Hallani S, Breau RH, Morash C, Robertson SJ, Mai KT, Belanger EC, Flood TA.

Virchows Arch. 2015 Oct;467(4):437-42. doi: 10.1007/s00428-015-1809-5. Epub 2015 Jul 31.

PMID:
26229020
16.

Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.

Shukla-Dave A, Hricak H, Akin O, Yu C, Zakian KL, Udo K, Scardino PT, Eastham J, Kattan MW.

BJU Int. 2012 May;109(9):1315-22. doi: 10.1111/j.1464-410X.2011.10612.x. Epub 2011 Sep 20.

17.

Multiparametric magnetic resonance imaging of the prostate aids detect lesion progression.

Johnson LM, Rothwax JT, Turkbey B, Rais-Bahrami S, Wood BJ, Figg WD, Choyke PL, Merino MJ, Pinto PA.

J Comput Assist Tomogr. 2014 Jul-Aug;38(4):565-7. doi: 10.1097/RCT.0000000000000069.

18.

Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.

Goris Gbenou MC, Peltier A, Addla SK, Lemort M, Bollens R, Larsimont D, Roumeguère T, Schulman CC, van Velthoven R.

Urol Int. 2012;88(1):12-7. doi: 10.1159/000331909. Epub 2011 Oct 15.

PMID:
22004874
19.

Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy.

Vilanova JC, Comet J, Barceló-Vidal C, Barceló J, López-Bonet E, Maroto A, Arzoz M, Moreno A, Areal J.

Radiology. 2009 Oct;253(1):135-43. doi: 10.1148/radiol.2531082049. Epub 2009 Jul 31.

PMID:
19703854
20.

Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.

Wong LM, Toi A, Van der Kwast T, Trottier G, Alibhai SM, Timilshina N, Evans A, Zlotta A, Fleshner N, Finelli A.

J Urol. 2014 Oct;192(4):1088-93. doi: 10.1016/j.juro.2014.04.010. Epub 2014 Apr 15.

PMID:
24742593

Supplemental Content

Support Center